Bio-Rad Laboratories BIO
United StatesHealthcare · Medical DevicesUSD
328.33 USD (−10.8%)
3 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Bio-Rad Laboratories is a US medical devices and diagnostics company that develops, manufactures, and sells life science research systems and clinical diagnostic products for laboratories, hospitals, and universities.
Key points
from its scores- ✓Good share-price trend7.9
- ✓Very solid balance sheet7.6
- ✕Little or no dividend1.5
- ✕Demanding valuation2.5
- ✕Little competitive advantage4.5
AI analysis
bottom line, main risk, context and newsThe strength of the balance sheet and positive momentum do not offset a valuation that already discounts growth that revenues are not showing; wait for a better price-to-growth relationship or confirmation of accelerating sales.
Bio-Rad has a very solid balance sheet (net cash, 3.14 liquidity) and good momentum (24.05% over 12 months), but its valuation is demanding: a 46.6x P/E with an ROIC of only 3.4% and an ROE of 3.1%, while revenue falls 0.1%. The market is discounting growth that current fundamentals do not confirm, and the rise in US rates adds pressure to the multiple.
The main risk is valuation: trading at 46.6x earnings with an ROIC of 3.4% and a 0.1% revenue decline leaves little room for error if expected growth does not materialize or if rates continue to rise.
Context and risks
No relevant recent news. Bio-Rad's main risk is operational and valuation-related: it trades at a 46.6x P/E with an ROIC of 3.4% and an ROE of 3.1%, levels that reflect growth expectations that current revenues (which are falling 0.1%) do not confirm. The rising rate environment in the US adds pressure to an already demanding multiple, but there is no specific regulatory, geopolitical, or business model risk that justifies an additional adjustment.
Is Bio-Rad Laboratories stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 62% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 46.6 | 26.7 | +74% |
| EV / EBITDA | 21.7 | 14.5 | +50% |
| Price / book | 1.4 | 4.1 | −67% |
| Price / sales | 3.8 | 3.4 | +11% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 2.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 328.33 USD, −10.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 4.5 (sector 5.5), Growth 5.7 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 46.6
- Forward P/E
- 37.1
- EV / EBITDA
- 21.7
- Price / book
- 1.4
- Price / sales
- 3.8
- PEG
- 4.01
- Market cap
- 9.8B USD
- Enterprise value
- 9.6B USD
Profitability
- ROE
- 3.1%
- ROA
- 1.7%
- ROIC (approx.)
- 3.4%
- Gross margin
- 52.0%
- Operating margin
- 11.2%
- Net margin
- 8.6%
- Free cash flow
- 283.2M USD
- FCF yield
- 2.9%
- Cash conversion
- 64%
Solvency
- Total debt
- 1.4B USD
- Net debt
- −248.1M USD
- Cash
- 1.6B USD
- EBITDA
- 441.0M USD
- Net debt / EBITDA
- −0.56
- Debt / equity
- 19.10
- Current ratio
- 3.14
- Quick ratio
- 2.15
Growth
- Revenue growth
- −0.1%
- Earnings growth
- +18.7%
- EPS (TTM)
- 7.89 USD
- EPS (forward)
- 9.92 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.07
- Analyst consensus
- Hold (3)
- Target price
- 328.33 USD
- 52-week range
- 236.73 – 396.23
Recent news
All BIO news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Bio-Rad Laboratories
Is Bio-Rad Laboratories stock cheap or expensive?
On P/E and EV / EBITDA, it trades 62% above the Healthcare median on average. Valuation score: 2.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 328.33 USD, −10.8% versus the price. This is not investment advice.
What score does Bio-Rad Laboratories get on MeridIAn Screener?
It scores 4.9 out of 10, rank 1,728 of 2,130 (better than 17% of the companies analysed). Its strongest category is Momentum (7.9) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Bio-Rad Laboratories's P/E ratio?
Its P/E is 46.6: the share price equals 46.6 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 37.1.
How much is Bio-Rad Laboratories worth on the stock market?
Its market capitalisation is 9.8B USD and its enterprise value, debt included, is 9.6B USD.
How much debt does Bio-Rad Laboratories have?
It has more cash than debt: net cash of 248.1M USD.
Does Bio-Rad Laboratories pay a dividend?
It pays no dividend, or almost none.
How has Bio-Rad Laboratories stock performed over the last year?
It has risen 23.6% over the last year, excluding dividends. Over the last 52 weeks it has traded between 236.73 and 396.23 USD. Past performance does not guarantee future results.
What do analysts think of Bio-Rad Laboratories?
3 analysts cover it; their average recommendation is “Hold” and their average target is 328.33 USD (−10.8% versus the price). It is an estimate, not market data.